The Fresenius Kabi Simplist Glycopyrrolate injection, USP, represents the most recent manufacturer-prepared product available in the company’s proprietary, ready-to-administer portfolio of Simplist prefilled syringes, which the company designed to reduce the amount of time nurses spend preparing doses and documenting waste.
Lake Zurich, Illinois-based Fresenius Kabi’s Glycopyrrolate injection, USP 0.6 mg per 3 mL Simplist prefilled syringe may be administered prior to or concomitantly with Simplist Neostigmine Methylsulfate Injection, USP 3 mg per 3 mL prefilled syringe for the reversal of neuromusclar blockade, according to a news release.
“Fresenius Kabi is focused on helping reduce clinician burden by expanding our ready-to-administer offerings,” said John Ducker, president and CEO of Fresenius Kabi USA. “We’re pleased that our Simplist prefilled syringe portfolio now includes Glycopyrrolate injection, USP, which will minimize preparation complexity to streamline workflows and help support patient safety in the U.S.”
The company said it continues to invest in expanding its suite of ready-to-administer offerings to assure pharmacists and nurses have a wide range of prefilled, standard strengths, single-patient delivery system options, from bags to syringes, that streamline medication management form the pharmacy to the bedside, thus eliminating the steps in which errors can occur.
Fresenius Kabi’s Simplist Glycopyrrolate injection, USP, is formulated, filled and packaged in the U.S., the company said. Additionally, it is said to represent the company’s commitment to investing “more in America,” as Fresenius Kabi looks to focus efforts on providing more supply, more science, more support and more care to its customers and the patients they serve in the U.S.
To date, the company has invested nearly $1 billion to modernize and expand advanced U.S. pharmaceutical production and distribution facilities.
